Effective dose range of enalapril in mild to moderate essential hypertension.

British Journal of Clinical Pharmacology

Volumn 19, Issue 5, 1985, Pages 605-611

  Bergstrand, R ^a   Herlitz, H ^a   Johansson, S ^a   Berglund, G ^a   Vedin, A ^a   Wilhelmsson, C ^a   Gomez, HJ ^a   Cirillo, VJ ^a   Bolognese, JA ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; ENALAPRIL MALEATE; PLACEBO;

ADVERSE DRUG REACTION; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE; DRUG RESPONSE; DRUG THERAPY; ESSENTIAL HYPERTENSION; HUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; THERAPY; VERTIGO;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PULSE;

EID: 0022181965     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1985.tb02687.x     Document Type: Article

References (24)

1. Three new long‐acting converting‐enzyme inhibitors: relationship between plasma converting enzyme activity and response to angiotensin I
2. Antihypertensive therapy with MK‐421: angiotensin II‐renin relationships to evaluate efficacy of converting enzyme blockade
3. Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril
4. A comparative pilot study of enalapril, a new convertine enzyme inhibitor, and hydrochlorothiazide in essential hypertension
5. Captopril in the treatment of mild essential hypertension
6. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor ‘MK‐421
7. Angiotensin converting enzyme inhibitors: the clinical pharmacology of captopril and enalapril maleate
8. The clinical pharmacology of enalapril
9. Enalapril attenuates hydrochlorothiazide‐induced hypokalemia, hyperglycemia, hyperuricemia and hypercholesterolemia
10. Analysis of categorical data by linear models
11. Enalapril (MK‐421) in the treatment of hypertension with renal artery stenosis
12. Reflex‐hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK‐421 in normal humans
13. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK‐421 (enalapril) and MK‐521
14. A new class of angiotensin‐converting enzyme inhibitors
15. Captopril in essential hypertension
16. Enalapril and autonomic reflexes and exercise performance
17. Long‐term captopril treatment in moderate to severe hypertension
18. Increased renal plasma flow in long‐term enalapril treatment of hypertension
19. Long‐term efficacy of angiotensin‐converting‐enzyme inhibition with captopril in mild‐to‐moderate essential hypertension
20. A controlled multiclinic study to compare the antihypertensive effect of MK‐421, hydrochlorothiazide, and MK‐421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension
21. Captopril
22. Captopril: clinical pharmacology and benefit‐to‐risk ratio in hypertension and congestive heart failure
23. Enalapril in low‐renin essential hypertension